Navigation Links
Lexicon Pharmaceuticals Reports on Clinical Program Status and 2011 Third Quarter Results
Date:11/1/2011

THE WOODLANDS, Texas, Nov. 1, 2011 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease, today updated its drug development progress and reported financial results for the three and nine months ended September 30, 2011.

"Recent positive results from clinical studies of LX4211 and LX1032 have provided further validation for the unique mechanisms of action of these first-in-class drugs," said Dr. Arthur T. Sands, president and chief executive officer of Lexicon.  "We are progressing with plans to partner LX1032 on the strength of our Phase 2 data in carcinoid syndrome, and are engaged in active discussions with multiple parties about the program."

Progress in Clinical Pipeline

  • Telotristat etiprate (LX1032):  Results from the recently-completed placebo-controlled Phase 2 clinical trial of telotristat etiprate in carcinoid syndrome patients were reported at the annual meeting of the North American Neuroendocrine Tumor Society.  Telotristat etiprate, an inhibitor of tryptophan hydroxylase that reduces peripheral serotonin production without affecting brain serotonin levels, showed evidence of efficacy across several endpoints, including observed reductions in bowel movement frequency; decreased urinary 5-HIAA, a biomarker of serotonin synthesis; and improvements in patient-reported relief of symptoms.  Also reported were preliminary data from an ongoing open-label Phase 2 trial, which indicate that telotristat etiprate is producing biochemical and clinical benefits, including improvements in bowel movement frequency, flushing episode frequency, urinary 5-HI
    '/>"/>

  • SOURCE Lexicon Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8

    Related medicine technology :

    1. Lexicon to Provide Clinical Pipeline Update and Report Third Quarter 2011 Financial Results
    2. Lexicon Presents LX4211 Clinical Data at European Association for the Study of Diabetes Annual Meeting
    3. Lexicon Pharmaceuticals to Present at Morgan Stanley Global Healthcare Conference
    4. Lexicon Pharmaceuticals to Present at Stifel Nicolaus Healthcare Conference
    5. Lexicon Pharmaceuticals to Present at the Wedbush 2011 Life Sciences Management Access Conference
    6. Lexicon Announces Publication of Results From the Phase 2 Trial of LX1031 in Patients With Irritable Bowel Syndrome in Journal of Gastroenterology
    7. Phase 2 Trial of Lexicons LX1032, Telotristat Etiprate, Shows Positive Results in Carcinoid Syndrome
    8. Lexicon Pharmaceuticals Reports on Clinical Program Status and 2011 Second Quarter Results
    9. Lexicons IBS Drug Candidate, LX1033, Successfully Completes Phase 1 Clinical Trial
    10. Lexicon Presents LX4211 Mechanism of Action Data at American Diabetes Association Meeting and Announces Commencement of Phase 2b Clinical Trial in Type 2 Diabetes
    11. Lexicon Pharmaceuticals Announces Webcast of 2011 Annual R&D Day
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:1/23/2015)... Feffer LLP ( www.hfesq.com ) is investigating potential claims ... or the "Company") (NASDAQ: ADXS ), concerning ... shareholders. On January 21, 2015, an article ... had misrepresented the clinical data for its ADXS-HPV drug ...
    (Date:1/23/2015)... , Jan. 23, 2015  iMD Companies, Inc. (ICBU) has repositioned ... market share and grab a foothold in the hydroponic, hemp ... capabilities and a presence in the sector, and recently partnering ... growth of hemp and medical marijuana, iMD is committing to ...
    (Date:1/23/2015)... 23, 2015  CytoSorbents Corporation (NASDAQ CM: CTSO), a ... cytokine adsorber to reduce deadly inflammation in critically-ill ... $385,642, net of transaction costs, in non-dilutive funding ... Tax Certificate Transfer Program sponsored by the New ...
    Breaking Medicine Technology:Harwood Feffer LLP Announces Investigation of Advaxis, Inc. 2iMD Companies Poised to Make Impact in Multi-Billion Dollar Medical Marijuana Sector With Recent Investments and Strategic Partnerships 2CytoSorbents Receives $385,000 in Non-Dilutive Funding from the New Jersey Technology Business Tax Certificate Transfer Program 2CytoSorbents Receives $385,000 in Non-Dilutive Funding from the New Jersey Technology Business Tax Certificate Transfer Program 3
    ... NATICK, Mass., May 6, 2011 Boston Scientific ... the launch and first implants of its ENERGEN™ ... implantable cardioverter defibrillators (ICDs) in Europe and other ... thinnest high-energy devices to treat heart failure and ...
    ... BD Diagnostics, a segment of BD (Becton, Dickinson and ... launch of the BD MAX™ Open System for molecular testing, ... developed assays and offer enhanced testing services that elevate the ... the launch announcement on the opening day of the 21st ...
    Cached Medicine Technology:Boston Scientific Begins International Launch and First Implants of Next-Generation Devices to Treat Heart Failure and Sudden Cardiac Death 2Boston Scientific Begins International Launch and First Implants of Next-Generation Devices to Treat Heart Failure and Sudden Cardiac Death 3Boston Scientific Begins International Launch and First Implants of Next-Generation Devices to Treat Heart Failure and Sudden Cardiac Death 4BD Launches BD MAX™ Open System in Europe and Reveals Strategy to Build Broad Menu of Assays that Provide Timely, Accurate Information to Laboratories and Clinicians 2BD Launches BD MAX™ Open System in Europe and Reveals Strategy to Build Broad Menu of Assays that Provide Timely, Accurate Information to Laboratories and Clinicians 3BD Launches BD MAX™ Open System in Europe and Reveals Strategy to Build Broad Menu of Assays that Provide Timely, Accurate Information to Laboratories and Clinicians 4
    (Date:1/22/2015)... Angelweddingdress is a famous wedding dress company ... to follow it on Facebook, Twitter, and Pinterest. The fans ... Angelweddingdress draws a lottery every week. , Moreover, the company ... 2015. Click Angelweddingdress homepage for more information. ...
    (Date:1/22/2015)... AngelWeddingDress, the premier women’s dress supplier, has ... View website of AngelWeddingDress.com to find more ... dresses online for a bridal party. AngelWeddingDress offers a ... them. Its maternity wedding dresses are specially designed for ...
    (Date:1/22/2015)... Juvent Sports ( http://www.juventsports.com ) and David Leadbetter ... to bestow a Juvent Sports Achievement award upon an ... The award commemorated and congratulated McKitrick for her record ... her first amateur tournament in 1979 and most recently ...
    (Date:1/22/2015)... York, New York (PRWEB) January 22, 2015 ... filed after Fresenius Medical Care recalled its GranuFlo and ... federal multidistrict litigation underway in U.S. District Court, District ... Order dated January 20th, the Court has remanded a ...
    (Date:1/22/2015)... For over 20 years, Dr. David Cruz of Cruz ... has treated just about every type of injury that can result ... those same twenty-plus years, the team at Doctors on Liens ... best possible doctor. With the combined breadth of experience ...
    Breaking Medicine News(10 mins):Health News:Angelweddingdress Invites Its Customers To Follow It On Facebook, Twitter, And Pinterest 2Health News:AngelWeddingDress Has Recently Released Its Collection Of 2015 Maternity Wedding Dresses 2Health News:All-Time Leading Female Amateur Golfer Arlene McKitrick Receives Juvent Sports Achievement Award at 2015 PGA Show 2Health News:All-Time Leading Female Amateur Golfer Arlene McKitrick Receives Juvent Sports Achievement Award at 2015 PGA Show 3Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 3Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 4Health News:Industry Leading Chiropractor in Oceanside Joins the Doctors on Liens Network 2
    ... taking common antibacterial medication , THURSDAY, July 2 (HealthDay ... can cause sensorineural hearing loss, finds a new study. ... fibrosis patients treated over a 13-year period at Children,s ... them suffered from sensorineural hearing loss. Of those seven ...
    ... 2 Cardinal Health today announced that Bruce L. Downey ... completion of the planned spinoff of CareFusion Corporation, replacing John ... reasons after 22 years of service to the company as ... former chairman and chief executive officer of Barr Pharmaceuticals, Inc. ...
    ... ... contest for the best new industry application of its hand-centric motion capture and ... offers the most sophisticated hand-centric motion capture solutions in the marketplace. The winner ... free use for 12 months to develop their winning industry-application concept! , ...
    ... ,Help is Here Express, bus tour will be stopping in ... at various cities in order to help uninsured and ... medicines for free or nearly free. With the state,s unemployment ... year ago, the Partnership for Prescription Assistance (PPA) is ready ...
    ... , This release is available in Spanish ... of this kind of humour) favour the mental mechanisms which ... macho attitudes. Those are the conclusions of a study carried ... be released tomorrow Thursday 2nd of July in the framework ...
    ... SETO Holdings, Inc. (Pink Sheets: SETO) is pleased ... Virginia at 1244 Sycamore Sq. (Shopping Center), Midlothian (Richmond, VA). ... can go to ADVANCED,s web site (877allears.com) or contact Richard ... , , Forward-Looking Statements: Statements in this new ...
    Cached Medicine News:Health News:Cardinal Health Appoints Bruce Downey to Board of Directors; John McCoy Retires From Board After 22 Years 2Health News:CyberGlove Systems Hosts Worldwide Contest for New Motion Capture Technology Applications 2Health News:CyberGlove Systems Hosts Worldwide Contest for New Motion Capture Technology Applications 3Health News:Partnership for Prescription Assistance Prepared to Help North Dakota Workers Hurt by Recession 2Health News:Partnership for Prescription Assistance Prepared to Help North Dakota Workers Hurt by Recession 3Health News:Partnership for Prescription Assistance Prepared to Help North Dakota Workers Hurt by Recession 4Health News:Sexist jokes favor the mental mechanisms that justify violence against women 2
    ... The Laserex Tango ophthalmic laser system ... an SLT laser and a photodisruptor for ... is a frequency-doubled Nd:YAG producing pulsed 532 ... Nd:YAG producing 1064 nm. The appropriate laser ...
    Flat handle cross action....
    Thin and smooth jaws, cross action....
    ... the first of its kind. This Inserter ... minimal incision. The special direct-acting blades gently ... complete control and predictability. The gradual curve ... and the instrument has a recessed lock ...
    Medicine Products: